science

Tenofovir alafenamide

Tenofovir alafenamide is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Tenofovir alafenamide rather than just read about it. In short: Tenofovir alafenamide (TAF), sold under the brand name Vemlidy, is an antiviral medication used against hepatitis B and HIV. It is used for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease and is given in combination with other medications for the prevention and treatment of HIV.

Key takeaways

Tenofovir alafenamide belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Tenofovir alafenamide to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Tenofovir alafenamide from memory before moving on to harder problems.

Reference excerpt

Tenofovir alafenamide (TAF), sold under the brand name Vemlidy, is an antiviral medication used against hepatitis B and HIV. It is used for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease and is given in combination with other medications for the prevention and treatment of HIV. It is taken by mouth. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor and is a prodrug of tenofovir. It was developed by Gilead Sciences based on the protide technology of Chris McGuigan and is applied in the form of tenofovir alafenamide fumarate (TAF). Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (TDF), TAF has greater antiviral activity and better distribution into lymphoid tissues than that agent. It was approved for use in the US for HIV in 2015, and for hepatitis B in 2016. Although the US Food and Drug Administration (FDA) has approved tenofovir alafenamide for manufacture as a generic medication, it is not available. A generic combination of Emtricitabine/tenofovir alafenamide (Viatris) received marketing authorization in the European Union in July 2025.

Fixed-dose combinations containing tenofovir alafenamide

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) — approved both in the United States and in the European Union in November 2015, (compare elvitegravir/cobicistat/emtricitabine/tenofovir; (Stribild)) Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey) — approved in the United States in March 2016, and in the European Union in June 2016, (compare Emtricitabine/rilpivirine/tenofovir; (Complera)) Emtricitabine/tenofovir alafenamide (Descovy) — approved in the European Union and the United States in April 2016 (compare emtricitabine/tenofovir; (Truvada)). In October 2019, Descovy was approved in the United States for HIV-1 pre-exposure prophylaxis (PrEP). Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) — approved in the United States in February 2018. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza) — approved in the European Union in September 2017, in the United States in July 2018, and in Australia in November 2019. Dolutegravir/emtricitabine/tenofovir alafenamide. Dolutegravir/lamivudine/tenofovir alafenamide.

Research Gilead announced a Phase III clinical trial evaluating a single-tablet regimen combining tenofovir alafenamide with cobicistat, emtricitabine and elvitegravir and developed a coformulation of the drug with cobicistat, emtricitabine and the protease inhibitor darunavir. In a 48-week study comparing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (Stribild) to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya), the results showed the newer drug's effects to be non-inferior to the established agent, but at much lower dosages and with lower incidence of adverse side effects such as impaired kidney function. The FDA approved the TAF-based treatment regimen for treatment of HIV-1 in November 2015. Genvoya is the first TAF-based regimen to receive approval.

References

Illustrations

Worked examples

Example 1 — a first encounter with Tenofovir alafenamide

Start with the simplest possible case. Write down what Tenofovir alafenamide claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Tenofovir alafenamide before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Tenofovir alafenamide ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Tenofovir alafenamide

In research: Tenofovir alafenamide appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Tenofovir alafenamide in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Tenofovir alafenamide is common in secondary-school and first-year university syllabi. It links to neighbouring topics Carboxylate esters, Fixed dose combination (antiretroviral), Gilead Sciences, so understanding it makes those chapters shorter.
In everyday life: Look for Tenofovir alafenamide outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Tenofovir alafenamide” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Tenofovir alafenamide in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Tenofovir alafenamide means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Tenofovir alafenamide out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Tenofovir alafenamide in simple terms?

Why does Tenofovir alafenamide matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Tenofovir alafenamide?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Tenofovir alafenamide.